TABLA | Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung Cancer

Summary
Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed
each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds.
The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in
economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery
due to co-morbidities.

Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive
intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to
deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be
delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system.

The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading
companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking
funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval.
This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative
market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes
increase.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/950943
Start date: 01-06-2020
End date: 31-05-2023
Total budget - Public funding: 4 243 922,00 Euro - 2 994 613,00 Euro
Cordis data

Original description

Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed
each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds.
The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in
economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery
due to co-morbidities.

Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive
intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to
deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be
delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system.

The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading
companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking
funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval.
This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative
market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes
increase.

Status

CLOSED

Call topic

EIC-FTI-2018-2020

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-FTI-2018-2020
EIC-FTI-2018-2020